Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 18.07M P/E - EPS this Y - Ern Qtrly Grth -
Income -252.85M Forward P/E -15.47 EPS next Y - 50D Avg Chg 12.00%
Sales 117.63M PEG - EPS past 5Y 16.45% 200D Avg Chg 7.00%
Dividend N/A Price/Book 0.23 EPS next 5Y 46.00% 52W High Chg -40.00%
Recommedations 2.00 Quick Ratio 0.21 Shares Outstanding 1.24M 52W Low Chg 186.00%
Insider Own 0.69% ROA -5.77% Shares Float 1.22M Beta 1.46
Inst Own 13.22% ROE - Shares Shorted/Prior 8.10K/11.08K Price 14.85
Gross Margin 82.63% Profit Margin -214.95% Avg. Volume 57,637 Target Price -
Oper. Margin 3.90% Earnings Date May 2 Volume 3,453 Change 1.30%
About Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Acorda Therapeutics, Inc. News
04/15/24 Acorda Therapeutics Announces Delisting from Nasdaq
04/06/24 Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default
04/03/24 Acorda Therapeutics Announces Nasdaq Delisting Notification
04/02/24 Acorda files for bankruptcy, reveals asset sale plan
04/01/24 Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
04/01/24 Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
03/25/24 Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
01/11/24 Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
12/18/23 Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry
11/14/23 Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
11/13/23 Acorda Therapeutics Reports Third Quarter 2023 Financial Results
11/06/23 Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
11/06/23 Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
08/28/23 Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value
08/08/23 Acorda Therapeutics Reports Second Quarter 2023 Financial Results
08/02/23 Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: "For The Fighters™"
08/01/23 Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
06/28/23 Tom Burns Elected to the Acorda Therapeutics Board of Directors
06/26/23 Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
06/05/23 Little Excitement Around Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Revenues